ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NAUT vs PACB // DIVIDEND YIELD & FCF PAYOUT SAFETY

Nautilus Biotechnology Inc. (NASDAQ) VS. Pacific Biosciences of California Inc. (NASDAQ) • 15-METRIC TALLY: NAUT 0 — PACB 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NAUT VS. PACB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NAUT PACB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 28.60% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -12.99% -12.64% -0.35 PACB /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 57.4 61.4 -3.95 PACB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $399.9M $901.4M -$501.5M PACB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NAUT REV PACB REV NAUT GROSS % PACB GROSS % NAUT FCF PACB FCF
FY 2025 $0 $160.0M — 28.6% -$52.0M -$113.9M
FY 2024 $0 $154.0M — 24.2% -$61.3M -$212.2M
FY 2023 $0 $0 — — -$51.7M -$259.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NAUT // BETA —
PACB // BETA —